Venus Remedies Ltd received the first disbursement of â¹7.5 crore under the Governmentâs Production Linked Incentive (PLl) scheme for the financial year 2022-23, which covers 75% of the total incentive due to the company for the year.
The company has said that it belongs to the Category C of nan-MSME pharmaceutical companies chosen under the PLl scheme.
Commenting on the achievement, Saransh Chaudhary, CEO, Venus Medicine Research Centre, said, âWe are thrilled to receive the first disbursement under the PLl scheme, which emphasises our commitment to driving innovation, creating employment opportunities and contributing to the countryâs economic development.â
Venus Remedies stock inched up by 0.16 per cent on the NSE to trade at â¹338.25 as of 10.53 am on Wednesday.
Crime Today News | Markets | Commodities | Forex | Stocks
Source | Powered by Yes Mom Hosting
Crime Today News Agency